About Acetyl-CoA acetyltransferase, cytosolic
Acetyl-CoA acetyltransferase, cytosolic (ACAT2) is a protein
from Homo sapiens identified by UniProt accession
Q9BWD1, 397 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Acetyl-CoA acetyltransferase, cytosolic |
| UniProt accession | Q9BWD1 |
| Gene | ACAT2 |
| Organism | Homo sapiens |
| Length | 397 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- prostate carcinoma · score 0.14
- acetyl-CoA acetyltransferase-2 deficiency · score 0.12
- lipoprotein A measurement · score 0.05
- QRS complex · score 0.05
- electrocardiography · score 0.05
- QRS duration · score 0.05
- polycystic ovary syndrome · score 0.05
- adolescent idiopathic scoliosis · score 0.05
- low density lipoprotein cholesterol measurement · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BWD1-F1 | alphafold | PREDICTED | 97.21 | — |
Amino-acid sequence (397 residues)
MNAGSDPVVI VSAARTIIGS FNGALAAVPV QDLGSTVIKE VLKRATVAPE DVSEVIFGHV LAAGCGQNPV RQASVGAGIP YSVPAWSCQM ICGSGLKAVC LAVQSIGIGD SSIVVAGGME NMSKAPHLAY LRTGVKIGEM PLTDSILCDG LTDAFHNCHM GITAENVAKK WQVSREDQDK VAVLSQNRTE NAQKAGHFDK EIVPVLVSTR KGLIEVKTDE FPRHGSNIEA MSKLKPYFLT DGTGTVTPAN ASGINDGAAA VVLMKKSEAD KRGLTPLARI VSWSQVGVEP SIMGIGPIPA IKQAVTKAGW SLEDVDIFEI NEAFAAVSAA IVKELGLNPE KVNIEGGAIA LGHPLGASGC RILVTLLHTL ERMGRSRGVA ALCIGGGMGI AMCVQRE
Explore Acetyl-CoA acetyltransferase, cytosolic with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets